Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This study proposes to compare 2 different methods for managing a subject with psoriasis who
has achieved good disease control, as defined by a clinical response with a Physician Global
Assessment (PGA) inferior or equal to 1 at the screening visit, on etanercept treatment.
The first method involves stopping etanercept treatment on entry into the study, with the
option to reinitiate etanercept at 50 mg once weekly after medical review and agreement
between the subject and the investigator. The second method involves continuing on etanercept
at 25 mg once weekly, with the option to increase the dose to 50 mg once weekly after medical
review and agreement between the subject and the investigator. Subjects will be randomized
into one of these two study arms.